What question did this study set out to answer?

This study explores the impact of iron deficiency on the response to hydroxyurea in sickle cell disease patients.

December 8, 2025Blood

Iron deficiency limits hydroxyurea-induced fetal hemoglobin and clinical efficacy in sickle cell disease

View Full Paper

Ask AI

Bookmark

Authors

AHAnoosha Habibi YZYosr Zaouali NHNicolas Hebert

Discussion

Member takes

Overview

Observational study links iron deficiency to reduced fetal hemoglobin and increased vaso-occlusive crises in sickle cell disease patients on hydroxyurea therapy.

Key Points

This study explores the impact of iron deficiency on the response to hydroxyurea in sickle cell disease patients.
Analyzed clinical and biological data from patients with HbSS and Sβ⁰-thalassemia genotypes.
Data collected included hemoglobin levels, fetal hemoglobin percentage, and iron status.
Iron deficiency defined as transferrin saturation <20%.
Patients categorized based on hydroxyurea treatment and iron deficiency status.
Statistical comparisons made for various blood parameters.Us
Iron deficiency found in 43% of patients receiving hydroxyurea and 29% of untreated patients.
Patients on hydroxyurea with iron deficiency had higher vaso-occlusive crises compared to those without.
Iron status correlated negatively with fetal hemoglobin synthesis, increasing sickling risk in deficient patients.

Cite This Study

Habibi et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d70a https://doi.org/10.1182/blood-2025-299

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

Iron deficiency limits hydroxyurea-induced fetal hemoglobin and clinical efficacy in sickle cell disease

View Full Paper

Ask AI

Bookmark

Authors

AHAnoosha Habibi YZYosr Zaouali NHNicolas Hebert

Discussion

Member takes

Overview

Observational study links iron deficiency to reduced fetal hemoglobin and increased vaso-occlusive crises in sickle cell disease patients on hydroxyurea therapy.

Key Points

This study explores the impact of iron deficiency on the response to hydroxyurea in sickle cell disease patients.
Analyzed clinical and biological data from patients with HbSS and Sβ⁰-thalassemia genotypes.
Data collected included hemoglobin levels, fetal hemoglobin percentage, and iron status.
Iron deficiency defined as transferrin saturation <20%.
Patients categorized based on hydroxyurea treatment and iron deficiency status.
Statistical comparisons made for various blood parameters.Us
Iron deficiency found in 43% of patients receiving hydroxyurea and 29% of untreated patients.
Patients on hydroxyurea with iron deficiency had higher vaso-occlusive crises compared to those without.
Iron status correlated negatively with fetal hemoglobin synthesis, increasing sickling risk in deficient patients.

Cite This Study

Habibi et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d70a https://doi.org/10.1182/blood-2025-299

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark